Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rybrevant
Pharma
J&J's Rybrevant moves into first line in lung cancer subtype
While Takeda's Exkivity is out of the picture, ArriVent BioPharma and AstraZeneca spinout Dizal are each working on EGFR lung cancer meds.
Angus Liu
Mar 4, 2024 11:13am
ESMO: Should AZ worry about J&J's Tagrisso head-to-head win?
Oct 23, 2023 10:30am
After trial flop, Takeda to pull Exkivity worldwide
Oct 3, 2023 9:55am
J&J's Reybrevant combo bests AZ's Tagrisso in key study
Sep 28, 2023 11:16am
J&J touts Rybrevant win in newly diagnosed NSCLC
Jul 17, 2023 11:10am
After price deal, Takeda's Exkivity will be available soon in UK
Mar 21, 2022 12:26pm